

OREGON DRUG USE REVIEW BOARD

Thursday, Dec 16, 2010 2:00-5:00 PM

Human Services Building

500 Summer Street, NE

Salem, OR 97301

Meeting Minutes

I. CALL TO ORDER

Members Present: Stacy Ramirez, PharmD; Maggie Bennington-Davis, MD; Patrick Bowman, RPh; Laura DeSimone, RPh; Fara Etzel, MD; George Gerding, RPh; Robert Ingle, MD, MPH

Members Present by Phone: Jordan Laub, MD, MPH; Jennifer DeVoe, MD

Members not Present: Ann Hamer, PharmD; Deanna Bucki-Moretz, PharmD; David Evans, MD;

Staff Present: Kathy Ketchum, RPh; Domenica Oberholtzer, PharmD; Luke Middleton; Roger Citron, RPh; Dan Hartung, PharmD, MPH; Ralph Magrish (DHS); Rich Holsapple, RPh (HP); Roger Citron, RPh; Valerie Smith (DHS)

Guests Present: David Barba (Forest); Bruce Smith (GSK); Jennifer Briana (GSK); Barry Benson (Merck); Jenny Blackham (Lilly); Venus Holder (Lilly); Nate Miles (Lilly); Ben Michaels (OSU); Courtney Johnston (Rep. Val Hoyle); Gina Nikkel (AOCMHP); Tracy Davids (Lilly); Shannon Beatty (MedImmune); Michael Willett (Pfizer)

a. Dr. Bennington-Davis called the meeting to order shortly after 2pm. Board members were introduced. Guests were asked to sign in.

b. Membership was reviewed. Board members were asked to attend meetings in March and May. Future meetings will be discussed in more detail during the March meeting.

c. Conflict of Interest Declaration was reviewed and updated.

d. Agenda and previous minutes were approved.

e. Public comment was given by Jenny from Lilly. She presented information on Cymbalta.

II. OLD BUSINESS

a. LABA/ICS PA criteria to be updated with Dulera per new drug policy.

b. Dr. Oberholtzer presented on PA criteria for insulin pens. Discussion recommended eliminating #4 and adding "<18" to #5.

ACTION: Board approves criteria with changes.

c. Quantity limits will be discussed at next DUR Board meeting in March.

d. Mr. Citron presented on pediatric psychotropic use.

III. NEW BUSINESS

a. Mr. Citron presented a report done on methadone poisoning in Oregon.

ACTION: More information will be presented at the next meeting in March.

b. Mr. Hartung presented on a Lamictal substitution evaluation.

c. Ms. Ketchum presented on SNRI DUE / proposed PA criteria. Discussion recommended moving #2 to #7.

ACTION: Board approves criteria with changes.

d. 2011 proposed meeting dates are March 17th in Wilsonville and May 19th in Salem.

ACTION: Board approves meeting dates.

e. Further discussion will be had in March around the 2011 Officers. Dr. Bennington-Davis does not expect anyone to continue, but Dr. Etzel, Ms. Ramirez, & Mr.

Bowman are willing. Dr. Bennington-Davis will remain Chair through May meeting.

ACTION: Board approves Chair position carried out by Dr. Bennington-Davis through May.

IV. REPORTS

- a. Mr. Magrish updated that the Clozapine Management rule will not be repealed, DMAP will host a series of Webinar trainings on NDC billing requirements, and gave a reminder that the new AAAC pricing methodology will be effective January 1, 2011.
- b. Mr. Holsapple presented the ProDUR report. Lovenox was added to High Dose and the low dose Seroquel will become effective January 1, 2011.
- c. Dr. Oberholtzer presented the RetroDUR report.
- d. Mr. Citron presented the Quarterly Utilization Reports.
- e. Prescriber Tools Report
 - i. DUR Newsletter
http://pharmacy.oregonstate.edu/drug_policy/index.php?nav=newsletter
 - ii. Epocrates
<http://www.epocrates.com/>
 - iv. PA Criteria posted – New criteria effective January 1, 2011.
<http://www.dhs.state.or.us/policy/healthplan/guides/pharmacy/clinical.html>